Ascentage Pharma Group International (HK:6855) has released an update.
Ascentage Pharma Group International has announced a significant private placement agreement with Takeda International after market hours on June 14, 2024, involving the issue and allotment of 24,307,322 new shares at a total value of approximately US$75 million. The deal, which will be executed under the company’s General Mandate without additional shareholder approval, represents a premium ranging from 4.55% to 25.12% over recent closing prices. The successful completion of this transaction is still subject to certain conditions, and J.P. Morgan and Citi are acting as Structuring Agents.
For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.
